Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 300Fluorouracil 273Bevacizumab 238Gemcitabine 235Leucovorin 213Capecitabine 207pembrolizumab 202Nivolumab 158Irinotecan 158Cisplatin 150Specimen Handling 144Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 118Paclitaxel 109durvalumab 106Cetuximab 104Radiotherapy 99atezolizumab 94Drug Therapy 94Biopsy 93tislelizumab 81Albumin-Bound Paclitaxel 81Taxes 74Folfox protocol 68lenvatinib 67Carboplatin 66regorafenib 60Blood Specimen Collection 60sintilimab 54Ipilimumab 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paroxetine × Gastrointestinal × 1 year × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡